Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 426

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 426
---
 framework of the aforementioned collaboration and as preparation for the submission of an IND application in the future. In accordance with the agreement, Kadimastem will grant Pluri the right to use the knowledge developed by Kadimastem for the benefit of Pluri’s production of Kadimastem’s products, with the first phase lasting up to 12months, in consideration of approximately $70,000 to be paid in cash or through issuance of Company securities, as to be agreed upon by the parties. The Pluri Agreement further provides that after completion of first phase, subsequent phases of work may be initiated only upon written agreement of both parties, subject to capacity availability at Pluri’s facilities. Pricing for subsequent phases will be negotiated separately and is valid for 12months from June30, 2024. Kadimastem is responsible for providing all process and assay data, starting materials, and raw materials unless otherwise agreed, and may be charged a 15% handling fee on raw materials procured by Pluri. Kadimastem retains ownership of all materials and intellectual property provided under the Pluri Agreement, and grants Pluri a limited right to use such knowledge solely for the purpose of performing the services. The Pluri Agreement may be terminated: (i) by either party upon a material breach not cured within 30 days of notice; (ii) immediately by either party if the other becomes insolvent or subject to certain bankruptcy events; or (iii) by Kadimastem, without cause, upon 30 days’ written notice after the first 90 days of the agreement. In the event of termination, Kadimastem must pay for services rendered and non -cancellablecosts incurred up to the termination date. As of the date of this proxy statement/prospectus, $28,300 have been paid by Kadimastem to Pluri under this agreement. Intellectual Property Kadimastem seeks and has obtained some patent protection as well as other effective intellectual property rights for Kadimastem’s products and technologies in the United States and internationally. Kadimastem’s policy is to pursue, maintain and defend intellectual property rights developed internally and to protect the technology, inventions and improvements that are commercially important to the development of its business. A list of each of Kadimastem’s patent families, including each of their status, their filing locations, and application information, is set forth below:

| METHODS OF GENERATING GLIAL AND NEURONAL CELLS |     |           |     |            |